Oslo, Norway, June 3, 2021 - Reference is made to the Annual General Meeting of Vaccibody AS on May 5, 2021, where the issuance of Restricted Share Units (RSUs) to the new board member Birgitte Volck was approved. Birgitte Volck has been granted 4,674 RSUs in line with the terms set out in the minutes from the Annual General Meeting. 

Further, 200,000 share options have been granted to Mikkel Wandahl Pedersen in connection with his appointment as Chief Scientific Officer. The share options will have a strike price of NOK 81.14 per share, have a five-year term and will vest equally over a four-year vesting period. After the award of the share options, Mikkel Wandahl Pedersen holds a total of 200,000 share options and 0 shares.

Please see further details in attached document.